BBRP 11031
Alternative Names: BBRP-11031Latest Information Update: 19 Apr 2023
At a glance
- Originator BenoBio
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pancreatic cancer
Most Recent Events
- 13 Apr 2023 Beno Bio plans a phase I trial for pancreatic cancer in 2025 (Beno Bio pipeline, April 2023)
- 13 Apr 2023 Preclinical trials in Pancreatic cancer in South Korea (unspecified route) (Beno Bio pipeline, April 2023)
- 31 Dec 2020 Preclinical trials in Pancreatic cancer in South Korea, prior December 2020 (unspecified route) (BenoBio pipeline, April 2020)